GlassScriptPhysician profile
Alfred R Lonser
NPI 1245240308
$15,644.55
in general payments reported to CMS, 2019-2025
36 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $603 · 2021: $2,302 · 2022: $3,637 · 2023: $5,285 · 2024: $1,792 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,705 · Travel and Lodging: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,705.33 |
| Travel and Lodging | $1,656.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,323.66 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Accurian |
| Nevro Corp. | $2,327.34 | 2019-2024 | Senza |
| Abbott Laboratories | $1,066.21 | 2021-2025 | Proclaim, Eterna, Octrode |
| Mml US, INC. | $1,058.06 | 2022 | |
| Abbvie INC. | $982.25 | 2021-2025 | |
| Medtronic USA, INC. | $538.30 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $360.78 | 2019-2025 | Ajovy |
| Collegium Pharmaceutical, INC. | $296.28 | 2021-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $272.29 | 2025 | Senza, Vyrsa V1 |
| Biohaven Pharmaceutical Holding Company LTD. | $228.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.92 | 2021-2022 | |
| Pfizer INC. | $227.91 | 2019-2025 | |
| Amgen INC. | $212.62 | 2019-2022 | |
| Grt US Holding, INC. | $189.29 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $158.13 | 2021-2025 | Xeomin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $156.86 | 2019-2023 | |
| Boston Scientific Corporation | $136.61 | 2023-2025 | General - Gi Dilatation |
| Biohaven Pharmaceuticals, INC. | $111.05 | 2020-2021 | |
| Allergan, INC. | $101.60 | 2019-2020 | |
| Averitas Pharma INC. | $97.67 | 2023-2025 | Qutenza |
| Vertos Medical, INC. | $69.97 | 2024 | Mild Device Kit |
| Ibsa Pharma INC. | $57.30 | 2020-2023 | Tirosint, Licart |
| Lundbeck LLC | $54.69 | 2023-2025 | Vyepti |
| Pacira Therapeutics, INC. | $46.99 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $42.76 | 2020 | |
| Azurity Pharmaceuticals, INC. | $40.68 | 2023 | Horizant |
| Vertex Pharmaceuticals Incorporated | $40.27 | 2024 | |
| Alnylam Pharmaceuticals INC. | $39.74 | 2022 | |
| Piramal Critical Care | $29.67 | 2021-2025 | |
| Lilly USA, LLC | $28.65 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.99 | 2024 | Iovera |
| Tactile Systems Technology INC | $22.93 | 2020 | |
| Indivior INC. | $21.64 | 2020 | |
| Depuy Synthes Sales INC. | $20.74 | 2025 | Monovisc, Orthovisc |
| Bioventus LLC | $18.25 | 2019 | |
| Baudax Bio INC. | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Lonser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.